After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Theravance Biopharma Inc. (TBPH) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.32, or 2.81%, to $11.70. The Theravance Biopharma Inc. has recorded 6,464 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Stocks Info
As a NASDAQ listed company, TBPH falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $11.38 and fluctuated between $11.98 as its day high and $11.07 as its day low. The current market capitalization of Theravance Biopharma Inc. is $713.87M. A total of 0.65 million shares were traded on the day, compared to an average of 535.47K shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, TBPH has seen 7 BUY and 9 SELL insider trades, representing the acquisition of 646,819 and the disposition of 84,546 shares. Over the last 12 months, there were 8 BUYs and 31 SELLs from insiders. Insiders purchased 666,819 shares during that period but sold 10,072,210.
In the most recent transaction, GRAHAM RICHARD A sold 2,323 shares of TBPH for 11.88 per share on Apr 14. After the transaction, the SVP, RESEARCH & DEVELOPMENT now owns 369,494 company shares. In a previous transaction on Mar 14, GRAHAM RICHARD A sold 2,323 shares at 10.32 per share. TBPH shares that SVP, RESEARCH & DEVELOPMENT owns now total 371,817.
Among the insiders who sold shares, Farnum Rhonda disposed of 4,000 shares on Mar 09 at a per-share price of $10.20. This resulted in the SVP, COMM & MEDICAL AFFAIRS holding 360,190 shares of TBPH after the transaction. In another insider transaction, GRAHAM RICHARD A sold 2,323 shares at $10.05 per share on Mar 06. Company shares held by the SVP, RESEARCH & DEVELOPMENT now total 374,140.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for TBPH in the last 3 months, the mean price target is $14.00 with high estimates of $19.00 and low estimates of $9.00. In terms of 52-week highs and lows, TBPH has a high of $12.03 and a low of $7.53.
As of this writing, TBPH has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.15 per share and a lower estimate of -$0.26. The company reported an EPS of -$0.15 in the last quarter, which was 11.80% higher than expectations of -$0.17.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. TBPH’s latest balance sheet shows that the firm has $173.47M in Cash & Short Term Investments as of fiscal 2021. There were $652.08M in debt and $58.59M in liabilities at the time. Its Book Value Per Share was $6.56, while its Total Shareholder’s Equity was -$338.57M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TBPH is Buy with a score of 3.75.
